Evidence map›Paper›PMID 41951603›Full record

ArticleCell death & disease2026

RIP kinase inhibition with Necrostatin-1 improves human marginal mass islet graft survival and function for the management of type 1 diabetes.

Saloni Aggarwal, Nerea Cuesta-Gomez, Joy Paramor, Sandra Kelly, Kateryna Polishevska, Karen Seeberger, Jessica Worton, Purushothaman Kuppan, Andrew R Pepper

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Saloni Aggarwal *Department of Surgery, University of Alberta, Edmonton, AB, Canada.
Nerea Cuesta-Gomez *Department of Surgery, University of Alberta, Edmonton, AB, Canada.ORCID http://orcid.org/0000-0002-1976-6298
Joy ParamorDepartment of Surgery, University of Alberta, Edmonton, AB, Canada.ORCID http://orcid.org/0009-0008-6772-9062
Sandra KellyDepartment of Surgery, University of Alberta, Edmonton, AB, Canada.
Kateryna PolishevskaDepartment of Surgery, University of Alberta, Edmonton, AB, Canada.
Karen SeebergerDepartment of Surgery, University of Alberta, Edmonton, AB, Canada.ORCID http://orcid.org/0000-0002-4709-0723
Jessica WortonDepartment of Surgery, University of Alberta, Edmonton, AB, Canada.ORCID http://orcid.org/0009-0003-9175-6865
Purushothaman KuppanDepartment of Surgery, University of Alberta, Edmonton, AB, Canada.ORCID http://orcid.org/0000-0001-6256-7692
Andrew R PepperDepartment of Surgery, University of Alberta, Edmonton, AB, Canada. apepper@ualberta.ca.ORCID http://orcid.org/0000-0002-2227-4446

Funding

Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) 498342Juvenile Diabetes Research Foundation Canada (JDRF Canada) 5-CDA-2020-945-A-N
6 · The paper itself

Abstract

Islet transplantation (ITx) has demonstrated that cellular therapies can improve glycemic control in patients with type 1 diabetes. However, cell death in the acute post-transplant period accounts for the loss of up to 70% of the islets, resulting in the requirement of multiple donors per recipient to achieve normoglycemia. Several studies have targeted apoptosis prevention after ITx; herein, our study explores a novel approach by modulating RIPK1-associated stress pathways using Necrostatin-1 (Nec-1) to enhance human islet survival, engraftment, and function post-transplant. Nec-1 treatment for 24 h prior to transplant significantly reduced the expression of RIPK1 (p = 0.0021) and RIPK3 (p = 0.0042), resulting in decreased cell death (p < 0.0001) and necroptosis (p < 0.0001), measured as TUNEL

Indexed as

Diabetes Mellitus, Type 1Graft SurvivalImidazolesIndolesIslets of Langerhans TransplantationReceptor-Interacting Protein Serine-Threonine KinasesAnimalsApoptosisFemaleHumansIslets of LangerhansMaleImidazolesIndolesnecrostatin-1Receptor-Interacting Protein Serine-Threonine KinasesRIPK1 protein, human

Identifiers

PMID41951603
PMCPMC13187314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.